Navivumab

Navivumab Suppliers list
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 021-61312847; 18021002903
Email: 3008007409@qq.com
Products Intro: Product Name:Navivumab (anti-HA)
CAS:1443004-16-7
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K14653
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com
Products Intro: Product Name:Navivumab
CAS:1443004-16-7
Purity:95% Package:100ug;500ug;1mg
Company Name: Guangzhou Hongyuan Chemical Co.,Ltd  
Tel: 15817493340
Email: 981810490@qq.com
Products Intro: Product Name:Navivumab
CAS:1443004-16-7
Purity:95% Package:1mg;1g;100g
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Products Intro: Product Name:Navivumab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
Company Name: Biolab Reagents  
Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Products Intro: Product Name:Research Grade Navivumab (DVV03803)
CAS:1443004-16-7
Purity:PAGE:>95% Package:100ug;1mg
Navivumab Basic information
Product Name:Navivumab
Synonyms:Navivumab;Research Grade Navivumab (DVV03803);Research Grade Navivumab;Navivumab (anti-HA)
CAS:1443004-16-7
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Navivumab Structure
Navivumab Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Navivumab Usage And Synthesis
UsesNavivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2[1].
References[1] Beigel JH. Polyclonal and monoclonal antibodies for the treatment of influenza. Curr Opin Infect Dis. 2018 Dec;31(6):527-534. DOI:10.1097/QCO.0000000000000499
Navivumab Preparation Products And Raw materials
Tag:Navivumab(1443004-16-7) Related Product Information
Rosmantuzumab Cendakimab Gresonitamab Anrukinzumab Tibulizumab Lusvertikimab Talacotuzumab Ivicentamab Flanvotumab Firivumab